KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.

The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeu...

Full description

Bibliographic Details
Main Authors: Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, William Maltese, Luisa Manning, Neil Senzer, John Nemunaitis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5979018?pdf=render